AbbVie, Genmab Say Epkinly Didn't Prolong Overall Survival in Lymphoma Study

Why It Matters

The miss curtails AbbVie’s expected revenue boost from a new lymphoma therapy and signals heightened risk for ADC strategies in a competitive market.

Key Takeaways

• Epkinly did not improve overall survival in DLBCL
• Phase 3 trial met safety but missed primary efficacy endpoint
• Results may delay FDA submission for Epkinly
• AbbVie’s oncology revenue outlook weakened by failure
• Competing ADCs gain market momentum

Pulse Analysis

Diffuse large B‑cell lymphoma remains one of the most aggressive non‑Hodgkin cancers, driving intense research into targeted therapies. Epkinly, an antibody‑drug conjugate linking a CD30‑directed antibody to a cytotoxic payload, was designed to deliver chemotherapy directly to malignant B‑cells while sparing healthy tissue. The Phase 3 trial enrolled several hundred patients across multiple regions, aiming to demonstrate a survival advantage over standard R‑CHOP regimens. While the safety data aligned with expectations, the lack of overall‑survival benefit underscores the difficulty of translating promising early‑phase signals into definitive clinical outcomes.

For AbbVie, the trial’s failure disrupts a strategic pillar of its oncology pipeline, which has relied on ADCs to diversify beyond its blockbuster immunology franchise. The company had projected Epkinly to contribute several hundred million dollars in annual sales within five years, a forecast now in jeopardy. Genmab, the technology partner, also faces pressure to validate its ADC platform, potentially affecting future licensing deals. Investors have responded with a modest dip in AbbVie’s share price, and analysts are revising revenue guidance to reflect the delayed or possibly abandoned launch.

The broader market reaction highlights the competitive landscape for lymphoma treatments. Other ADCs, such as Pfizer’s tisotumab vedotin and Roche’s polatuzumab vedotin, continue to progress through late‑stage trials, positioning themselves as viable alternatives. The setback may accelerate interest in novel modalities like bispecific antibodies and CAR‑T therapies, which have shown durable responses in refractory DLBCL. Stakeholders will watch closely how AbbVie reallocates R&D resources and whether it can leverage its existing pipeline to offset the lost momentum from Epkinly’s disappointment.